Usefulness of the .ALPHA.1-Blocker Doxazosin as a Third-Line Antihypertensive Drug

Authors:

Abstract
It has been reported that a substantial majority of hypertensives receive insufficient blood pressure (BP) control. As combination therapy for the treatment of hypertension, Ca channel blockers (CCBs), angiotensin II (AII) receptor blockers (ARBs), and/or AII-converting enzyme (ACE) inhibitors are mainly prescribed, while the efficacy of α1-blockers in such combination therapy remains unknown. The aim of this study was to investigate the efficacy of a low dose of an α1-blocker added to combination therapy with CCBs and either ARBs or ACE inhibitors for the treatment of hypertension. Subjects were 41 hypertensive patients (23 women and 18 men, mean age 66±12 years) who had been followed at the National Kyushu Medical Center. All patients showed poor BP control despite haven taken a combination of CCBs and ARBs or ACE inhibitors for more than 3 months. Doxazosin at a dose of 1 to 2 mg was added to each treatment regimen. The changes in various clinical parameters, including BP and blood chemistry, following the addition of doxazosin were then evaluated. The mean follow-up period was 170 days. BP decreased from 152±14/81±12 mmHg to 135±14/70±11 mmHg after the addition of doxazosin at a mean dose of 1.5 mg/day (pppn=25) showed significantly higher baseline SBP, serum total cholesterol and low-density lipoprotein (LDL) cholesterol levels compared to those who showed less SBP reduction (n=16, pΔBP at 3 months: −15±15/−12±9 mmHg, n=18) and non-obese (BMIΔBP: −14±19/−7±8 mmHg, n=23) patients. The results suggest that addition of a low dose of the α1-blocker doxazosin effectively reduces BP in patients taking CCBs and ARBs or ACE inhibitors. Thus, doxazosin seems to be useful as a third-line antihypertensive drug.

This publication has 23 references indexed in Scilit: